Wall Street sees new obesity pills as priced near Wegovy and Zepbound

Wall Street analysts and investors expect Eli Lilly and Novo Nordisk's forthcoming oral obesity pills to be priced on par with their existing injectable GLP-1 drugs, such as Wegovy and Zepbound, rather than at a premium. This pricing strategy, a departure from typical new drug launches, is influenced by the oral drugs' comparable or lower efficacy compared to injections, significant market pressure for affordability, and the need to expand access. While these pills are projected to broaden the market and capture a mid-teens percentage of the global obesity drug market by 2030 (estimated at $150 billion), they are anticipated to fill a niche rather than displace the established injectable treatments, despite manufacturing complexities for the oral formulations.

Analysis

Wall Street expects forthcoming oral obesity drugs from Eli Lilly (LLY) and Novo Nordisk (NVO) to be priced on par with existing high-cost GLP-1 injections, a departure from the standard practice of launching new formulations at a premium. This pricing strategy is primarily constrained by the oral drugs' efficacy, which does not surpass that of the market-leading injectables; Lilly's orforglipron demonstrated 12.4% weight loss, while Novo's oral semaglutide showed 15%, both trailing the up to 21% efficacy of Lilly's Zepbound injection. The market reaction to this data has been notably negative for Eli Lilly, with peak annual sales forecasts for orforglipron being revised downward from as high as $30 billion to as low as $10 billion. Conversely, Novo Nordisk appears better positioned with a more effective oral drug, a clearer launch timeline, and management's confidence in overcoming significant manufacturing hurdles, despite the pill requiring 75 times more active ingredient. Analysts project these oral medications will serve a niche for injection-averse patients, capturing a mid-teens percentage of a global obesity market potentially worth $150 billion by 2030, rather than displacing the dominant injectable treatments.

Key Decisions for Investors

• Investors should recognize Novo Nordisk's potential near-term advantage in the oral obesity market, driven by its pill's superior efficacy data over Eli Lilly's offering and a more immediate launch horizon.
• Re-evaluate the future revenue contribution from Eli Lilly's orforglipron, as its peak sales forecasts have been drastically cut from $30 billion to as low as $10 billion, signaling tempered growth expectations for this specific product.
• Closely monitor Novo Nordisk's manufacturing scale-up, as the oral formulation's high active ingredient requirement presents a key execution risk that could constrain supply despite the company's stated confidence.
• View the oral drug launches as a market expansion strategy targeting new patient segments, rather than a direct threat that will cannibalize the highly profitable injectable GLP-1 franchise, which is expected to remain the dominant treatment form.